Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.430 -0.040 (-2.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023 ↗
For those that want to take a journey on the wild side of the market, these penny stocks may offer significant upside rewards. 
Via InvestorPlace
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte’s Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran’s TAILWIND® platform for novel CAR-NK cell therapies 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
News headline image
7 Hot Stocks to Book Profits In Before 2023 ↗
With major macroeconomic headwinds appearing on the horizon, it’s time for investors to consider the hot stocks to book profits in. 
Via InvestorPlace
News headline image
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
Curamys to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to help advance its cell fusion technology. 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2022 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Earnings Outlook For MaxCyte ↗
MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will... 
Via Benzinga
News headline image
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders ↗
MaxCyte Inc (NASDAQ: MXCT) has signed a  
Via Benzinga
News headline image
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Recap: MaxCyte Q2 Earnings ↗
  MaxCyte (NASDAQ:MXCT) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings MaxCyte reported in-line EPS of... 
Via Benzinga
News headline image
A Preview Of MaxCyte's Earnings ↗
  MaxCyte (NASDAQ:MXCT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that MaxCyte will... 
Via Benzinga
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
Earnings Scheduled For May 9, 2022 ↗
Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million. 
Via Benzinga
News headline image
MaxCyte's Return On Capital Employed Insights ↗
Benzinga Pro data, MaxCyte (NASDAQ:MXCT) reported Q4 sales of $10.15 million. Earnings fell to a loss of $4.87 million, resulting in a 81.85% decrease from last quarter. MaxCyte... 
Via Benzinga
News headline image
Earnings Scheduled For March 22, 2022 ↗
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.18 per share on revenue of $338.69 million. • HUYA (... 
Via Benzinga
News headline image
11 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares rose 35.6% to $2.17 during Monday's regular session. The current volume of 5.6 million shares is 531.8% of Aridis... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Pasithea Therapeutics (NASDAQ:KTTA 
Via Benzinga
News headline image
MaxCyte, Inc. (MXCT) Q3 2021 Earnings Call Transcript ↗
MXCT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
91 Biggest Movers From Yesterday ↗
Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Welcome back, investor! We're starting off the trading week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
News headline image
28 Stocks Moving In Friday's Mid-Day Session ↗
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR... 
Via Benzinga
News headline image
18 Stocks Moving in Friday's Pre-Market Session ↗
Gainers eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) rose 25.5% to $14.41 in pre-market trading after the company, in collaboration with investigators at Baylor College of Medicine... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.